Outcome research in palliative care: Could it represent a new dimension of clinical research or clinical practice?

Supportive Care in Cancer

Volumn 13, Issue 3, 2005, Pages 176-181

  Tassinari, Davide ^a,d   Maltoni, Marco ^b   Sartori, Sergio ^c   Fantini, Manuela ^a   Poggi, Barbara ^a   Ravaioli, Alberto ^a  

^a City Hospital   (Italy)

^b MORGAGNI PIERANTONI HOSPITAL   (Italy)

^c UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^d CPN 35 ^*  (Italy)

Author keywords

Cancer cachexia; Outcome research; Pharmacoeconomics

Indexed keywords

DEXAMETHASONE; FLUOXYMESTERONE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; PROGESTERONE DERIVATIVE;

CACHEXIA; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; COST; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; FOLLOW UP; HEALTH CARE QUALITY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

CACHEXIA; FEMALE; FORECASTING; HEALTH SERVICES RESEARCH; HUMANS; MALE; MEDICAL ONCOLOGY; NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); PALLIATIVE CARE; QUALITY OF LIFE; RESEARCH; RISK ASSESSMENT; SURVIVAL ANALYSIS; TERMINALLY ILL;

EID: 16344380461     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-004-0683-5     Document Type: Review

References (42)

1. ASCO (1996) Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 14:671-679
2. Belda-Iniesta C, DeCastro Carpeno J, Fresno Vara JA, et al (2003) Eicosapentanoic acid as a targeted therapy for cancer cachexia. J Clin Oncol 21:4657-4658
3. Beller E, Tattersall M, Lumley T, et al (1997) Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: a randomised placebo-controlled trial. Australasian Megestrol Acetate Cooperative Study Group. Ann Oncol 8:277-283
4. Bruera E, Ernst S, Hagen N, et al (1998) Effectiveness of megestrol acetate in patients with advanced cancer: a randomized double blind, crossover study. Cancer Prev Control 2:74-78
5. Bruera E, Neumann CM, Pituskin E, et al (1999) Thalidomide in patients with cachexia due to terminal cancer: preliminary report. Ann Oncol 10:857-859
6. Bruera E, Strasser F, Palmer JL, et al (2003) Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double blind, placebo-controlled study. J Clin Oncol 21:129-134
7. Cella D, Chang CH, Lai JS, et al (2002) Advances in quality of life measurements in oncology patients. Semin Oncol 29 [3 Suppl 8]:60-68
8. Cerchietti LCA, Navigante AH, Peluffo GD, et al (2004) Effects of celecoxib, medroxyprogesterone, and dietary intervention on systemic syndromes in patients with advanced lung adenocarcinoma: a pilot study. J Pain Symptom Manage 27:85-95
9. Davis MP, Dickerson D (2000) Cachexia and anorexia: cancer's covert killer. Support Care Cancer 8:180-187
10. De Conno F, Martini C, Zecca E, et al (1998) Megestrol acetate for anorexia in patients with far-advanced cancer: a double-blind controlled clinical trial. Eur J Cancer 34:1705-1709
11. Goodwin DM, Higginson IJ, Myers K, et al (2003) Effectiveness of palliative day care in improving pain, symptom control and quality of life. J Pain Symptom Manage 25:202-212
12. Hwang SS, Chang VT, Fairclough DL, et al (2003) Longitudinal quality of life in advanced cancer patients: pilot study results from a VA medical center. J Pain Symptom Manage 25:225-235
13. Inui AI (2002) Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J Clin 52:72-91
14. Jatoi A, Kumar S, Sloan JA, et al (2000) On appetite and its loss. J Clin Oncol 18:2930-2932
15. Jatoi A, Windschitl HE, Loprinzi CL, et al (2002) Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 20:567-573
16. Kaasa S, Loge JH (2002) Quality of life assessment in palliative care. Lancet Oncol 3:175-182
17. Kaasa S, Loge JH (2003) Quality of life in palliative care: principles and practice. Palliat Med 17:11-20
18. Kornek GV, Schenk T, Ludwig H, et al (1996) Placebo-controlled trial of medroxyprogesterone acetate in gastrointestinal malignancies and cachexia. Onkologie 19:164-168
19. Lee SJ, Craig CE, Weeks JC (2000) Outcomes research in oncology: history, conceptual framework, and trends in the literature. J Natl Cancer Inst 92:195-204
20. Loprinzi CL, Michalak D, Schaid DJ, et al (1993) Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J Clin Oncol 11:762-767
21. Loprinzi CL, Kugler JW, Sloan JA, et al (1999) Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol 17:3299-3306
22. Maltoni M, Nanni O, Scarpi E, et al (2001) High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: a systematic review of randomized clinical trials. Ann Oncol 12:289-300
23. Mantovani G, Macciò A, Lai P, et al (1998) Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate. Semin Oncol 25 [Suppl 2]:45-52
24. Nottage M, Siu LL (2002) Principles of clinical trial design. J Clin Oncol 20 (18s):42-46
25. Nelson KA (2000) The cancer anorexia-cachexia syndrome. Semin Oncol 27:64-68
26. Pascual Lopez A, Roque i Figuls M, Urrutia Cuchi G, et al (2004) Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. J Pain Symptom Manage 27:360-369
27. Potter J, Hami F, Bryan T, et al (2003) Symptoms in 400 patients referred to palliative care services. Prevalence and patterns. Palliat Med 17:310-314
28. Rowland KM, Loprinzi CL, Shaw EG, et al (1996) Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study. J Clin Oncol 14:135-141
29. Shorthouse K, Davies AN (2003) Symptom prevalence in palliative care. Palliat Med 17:723
30. Simon R (2000) Design and analysis of clinical trials. In: De Vita VT, Hellman S, Rosenberg SA (eds) Cancer. Principles and practice of clinical oncology. Lippincott Williams and Wilkins, Philadelphia, pp 521-538
31. Simons JP, Aaronson NK, Vansteenkiste JF, et al (1996) Effects of medroxyprogesterone acetate on appetite, weight and quality of life in advanced-stage non-hormone-sensitive cancer: a placebo-controlled multicentric study. J Clin Oncol 14:1077-1084
32. Sloan JA, Loprinzi CL, Kuross SA, et al (1998) Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer. J Clin Oncol 16:3662-3673
33. Somerfield M (2001) Hazards of quality-of-life data for clinical decision making. J Clin Oncol 19:594-595
34. Tassinari D (2003) Surrogate end point of quality of life assessment: have we really found what we are looking for? Health Qual Life Outcomes 1 (1):71
35. Tassinari D, Panzini I, Ravaioli A, et al (2002) Quality of life at the end of life: how is the solution far away? J Clin Oncol 20:1704-1705
36. Tassinari D, Panzini I, Sartori S, et al (2003) Surrogate outcomes in quality of life research: where we will end up? J Clin Oncol 21:1894-1895
37. Tassinari D, Poggi B, Fantini M, et al (2003) Can we really consider quality of life as an outcome of palliative care? J Pain Symptom Manage 26:886-887
38. Tchekmedyian NS, Hickman M, Siau J, et al (1992) Megestrol acetate in cancer anorexia and weight loss. Cancer 69:1268-1274
39. Tranmer JE, Coulson K (2003) Measuring the symptom experience of seriously ill cancer and non cancer patients near the end of life with the Memorial Symptom Assessment Scale. J Pain Symptom Manage 25:420-429
40. Vadell C, Seguì MA, Gimenez-Arnau JM, et al (1998) Anticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia. Am J Clin Oncol 21:347-351
41. Wall L (2003) Fish oil supplementation in patients with advanced cancer. J Clin Oncol 21:3545
42. Westman G, Bergman B, Albertsson M, et al (1999) Megestrol acetate in advanced progressive hormone-insensitive cancer. Effects on the quality of life: a placebo-controlled randomised multi-centre trial. Eur J Cancer 35:586-595